These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 12837154)
1. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154 [TBL] [Abstract][Full Text] [Related]
2. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808 [TBL] [Abstract][Full Text] [Related]
3. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Shen YY; Kao A; Yen RF Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600 [TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364 [TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Jerusalem G; Beguin Y; Najjar F; Hustinx R; Fassotte MF; Rigo P; Fillet G Ann Oncol; 2001 Jun; 12(6):825-30. PubMed ID: 11484959 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement. Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888 [TBL] [Abstract][Full Text] [Related]
12. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549 [TBL] [Abstract][Full Text] [Related]
13. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454 [TBL] [Abstract][Full Text] [Related]
14. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718 [TBL] [Abstract][Full Text] [Related]
15. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560 [TBL] [Abstract][Full Text] [Related]
16. Utility of Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587 [TBL] [Abstract][Full Text] [Related]
17. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420 [TBL] [Abstract][Full Text] [Related]
18. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169 [TBL] [Abstract][Full Text] [Related]
19. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235 [TBL] [Abstract][Full Text] [Related]
20. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]